OBJECTIVES: To test the feasibility and utility of a bedside geriatric assessment (GA) to detect impairment in multiple geriatric domains in older adults initiating chemotherapy for acute myelogenous leukemia (AML). DESIGN: Prospective observational cohort study. SETTING: Single academic institution. PARTICIPANTS: Individuals aged 60 and older with newly diagnosed AML and planned chemotherapy. MEASUREMENTS: Bedside GA was performed during inpatient exmination for AML. GA measures included the modified Mini-Mental State Examination; Center for Epidemiologic Studies Depression Scale; Distress Thermometer, Pepper Assessment Tool for Disability (includes self- reported activities of daily living (ADLs), instrumental ADLs, and mobility questions); Short Physical Performance Battery (includes timed 4-m walk, chair stands, standing balance); grip strength, and Hematopoietic Cell Transplantation Comorbidity Index. RESULTS: Of 54 participants (mean age 70.8 ± 6.4) eligible for this analysis, 92.6% completed the entire GA battery (mean time 44.0 ± 14 minutes). The following impairments were detected: cognitive impairment, 31.5%; depression, 38.9%; distress, 53.7%; impairment in ADLs, 48.2%; impaired physical performance, 53.7%; and comorbidity, 46.3%. Most were impaired in one (92.6%) or more (63%) functional domains. For the 38 participants rated as having good performance status according to standard oncologic assessment (Eastern Cooperative Oncology Performance Scale score ≤1), impairments in individual GA measures ranged from 23.7% to 50%. Significant variability in cognitive, emotional, and physical status was detected even after stratification according to tumor biology (cytogenetic risk group classification). CONCLUSION: Inpatient GA was feasible and added new information to standard oncology assessment, which may be important for stratifying therapeutic risk in older adults with AML.
OBJECTIVES: To test the feasibility and utility of a bedside geriatric assessment (GA) to detect impairment in multiple geriatric domains in older adults initiating chemotherapy for acute myelogenous leukemia (AML). DESIGN: Prospective observational cohort study. SETTING: Single academic institution. PARTICIPANTS: Individuals aged 60 and older with newly diagnosed AML and planned chemotherapy. MEASUREMENTS: Bedside GA was performed during inpatient exmination for AML. GA measures included the modified Mini-Mental State Examination; Center for Epidemiologic Studies Depression Scale; Distress Thermometer, Pepper Assessment Tool for Disability (includes self- reported activities of daily living (ADLs), instrumental ADLs, and mobility questions); Short Physical Performance Battery (includes timed 4-m walk, chair stands, standing balance); grip strength, and Hematopoietic Cell Transplantation Comorbidity Index. RESULTS: Of 54 participants (mean age 70.8 ± 6.4) eligible for this analysis, 92.6% completed the entire GA battery (mean time 44.0 ± 14 minutes). The following impairments were detected: cognitive impairment, 31.5%; depression, 38.9%; distress, 53.7%; impairment in ADLs, 48.2%; impaired physical performance, 53.7%; and comorbidity, 46.3%. Most were impaired in one (92.6%) or more (63%) functional domains. For the 38 participants rated as having good performance status according to standard oncologic assessment (Eastern Cooperative Oncology Performance Scale score ≤1), impairments in individual GA measures ranged from 23.7% to 50%. Significant variability in cognitive, emotional, and physical status was detected even after stratification according to tumor biology (cytogenetic risk group classification). CONCLUSION: Inpatient GA was feasible and added new information to standard oncology assessment, which may be important for stratifying therapeutic risk in older adults with AML.
Authors: Christian J Nelson; Christina Cho; Alexandra R Berk; Jimmie Holland; Andrew J Roth Journal: J Clin Oncol Date: 2009-12-07 Impact factor: 44.544
Authors: B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544
Authors: Steven Knapper; Alan K Burnett; Tim Littlewood; W Jonathan Kell; Sam Agrawal; Raj Chopra; Richard Clark; Mark J Levis; Donald Small Journal: Blood Date: 2006-07-20 Impact factor: 22.113
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Stefania Bandinelli; Fulvio Lauretani; Vittorio Boscherini; Francesca Gandi; Martina Pozzi; Anna Maria Corsi; Benedetta Bartali; Raffaello Molino Lova; Jack M Guralnik; Luigi Ferrucci Journal: Aging Clin Exp Res Date: 2006-10 Impact factor: 3.636
Authors: Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: Stephen P Messier; Richard F Loeser; Gary D Miller; Timothy M Morgan; W Jack Rejeski; Mary Ann Sevick; Walter H Ettinger; Marco Pahor; Jeff D Williamson Journal: Arthritis Rheum Date: 2004-05
Authors: Maria Queralt Salas; Eshetu G Atenafu; Ora Bascom; Leeann Wilson; Wilson Lam; Arjun Datt Law; Ivan Pasic; Dennis Dong Hwan Kim; Fotios V Michelis; Zeyad Al-Shaibani; Armin Gerbitz; Auro Viswabandya; Jeffrey Howard Lipton; Jonas Mattsson; Shabbir M H Alibhai; Rajat Kumar Journal: Bone Marrow Transplant Date: 2020-06-30 Impact factor: 5.483
Authors: Trevor A Jolly; Allison M Deal; Caroline Mariano; Nicole Markowski; Sharanda Kirk; Max S Perlmutt; Franklin Jones; Suel Ki Choi; Kirsten A Nyrop; Jan Busby-Whitehead; Hyman Muss Journal: Oncologist Date: 2020-01-27
Authors: Barbara Deschler; Gabriele Ihorst; Uwe Platzbecker; Ulrich Germing; Eva März; Marcelo de Figuerido; Kurt Fritzsche; Peter Haas; Helmut R Salih; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Theo de Witte; Pierre Wijermans; Michael Lübbert Journal: Haematologica Date: 2012-08-08 Impact factor: 9.941
Authors: Heidi D Klepin; Janet A Tooze; Timothy S Pardee; Leslie R Ellis; Dmitriy Berenzon; Shannon L Mihalko; Suzanne C Danhauer; Arati V Rao; Tanya M Wildes; Jeff D Williamson; Bayard L Powell; Stephen B Kritchevsky Journal: J Am Geriatr Soc Date: 2016-09-14 Impact factor: 5.562